The impact of religion on medication compliance

Article

Religiously-motivated fasting may affect glaucoma medication compliance rates, according to study results presented at the annual meeting of the American Academy of Ophthalmology (AAO).

Religiously-motivated fasting may affect glaucoma medication compliance rates, according to study results presented at the annual meeting of the American Academy of Ophthalmology (AAO).

Following on from an initial study assessing medication compliance rates in Muslims during the mandatory fasting period of Ramadan, Nishant Kumar, MBBS of University Hospital, Liverpool, UK and colleagues analyzed 350 surveys completed by respondents self-identified as members of the following faiths: Islam, Christianity, Judaism, Hinduism, Buddhism, Jainism and Bahá'í.

Dr Kumar’s initial study in Muslims showed significantly reduced medication compliance rates during Ramadan, as, during this period, Muslims abstain from fluid as well as food. This period of non-compliance was significant enough that an adverse effect on vision was possible. In the new study, the majority of Hindu, Muslim and Jain respondents stated that they would be unlikely to use eye drops during periods of fasting except in the case of severe pain or advanced disease, while the respondents of other religious beliefs stated that they were likely to remain compliant with their medication.

The team concluded that these periods of fasting have a potential impact on medication compliance, and therefore disease progression; it is essential that ophthalmologists are aware of their patients’ religious beliefs in order to formulate appropriate disease management plans.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.